IPO Details

Bidding Dates

11 Dec '24 - 13 Dec '24

Minimum Investment

₹14,823 / 1 Lot (27 Shares)

Price Range

₹522 - ₹549

Maximum Investment

₹1,92,699 / 13 Lot (351 Shares)

Retail Discount

To be announced

Issue Size

₹3,042.62 crore

Investor category and sub category

Retail Individual Investors (RII)  |   Non-institutional Investors (NII)  |   Qualified Institutional Buyers (QIB)  |  

Sai Life Sciences IPO Dates

Important dates with respect to IPO allotment and listing

Opening Date

Dec 11, 2024

Closing Date

Dec 13, 2024

Basis of Allotment

Dec 16, 2024

Initiation of Refunds

Dec 17, 2024

Listing Date

Dec 18, 2024

About Sai Life Sciences IPO

Sai Life Sciences IPO is a book-built issue aiming to raise ₹3,042.62 crore. It includes a fresh issue of 1.73 crore shares worth ₹950.00 crore and an offer for sale of 3.81 crore shares amounting to ₹2,092.62 crore. 

The IPO opens for subscription on December 11, 2024, and closes on December 13, 2024. Allotment is expected on December 16, 2024, with the listing anticipated on December 18, 2024, on both the BSE and NSE.

The IPO price band is set at ₹522 to ₹549 per share, with a minimum lot size of 27 shares. Retail investors need a minimum investment of ₹14,823. For non-institutional investors, small NII can invest in 14 lots (378 shares) worth ₹2,07,522, while large NII require 68 lots (1,836 shares) amounting to ₹1,007,964.

Kotak Mahindra Capital, Jefferies India, Morgan Stanley India, and IIFL Securities are the book-running lead managers. Kfin Technologies Limited is the registrar for the issue. Investors can refer to the Sai Life Sciences IPO RHP for detailed information about the offering.

Industry Outlook

  1. The global pharmaceutical market, valued at USD 1,451 billion in 2023, is expected to grow at a CAGR of 6.2% to reach USD 1,956 billion by 2028. This growth is driven by factors like an aging population, rising chronic diseases, and increased health consciousness. 
  2. India's Contract Research, Development, and Manufacturing Organisation (CRDMO) industry is projected to grow by 14% annually, from USD 7.3 billion in 2023 to USD 14.1 billion by 2028.
  3. The pre-clinical development segment in India's CRDMO industry is expected to grow at a CAGR of 15.7% from FY23 to FY28. This growth is driven by enhanced R&D capabilities in India.

Sai Life Sciences IPO Objectives 

The company plans to allocate the net proceeds from the issuance to the following purposes:

  1. The funds will be used to repay or prepay outstanding borrowings, either in full or part, reducing the company’s debt burden.
  2. The remaining funds will be allocated towards general corporate purposes.

About Sai Life Sciences Limited 

Sai Life Sciences Limited is a leading Contract Research, Development, and Manufacturing Organisation (CRDMO) that provides comprehensive services across the drug discovery, development, and manufacturing value chain. The company serves global pharmaceutical and biotechnology firms, offering both contract research (CRO) and contract development and manufacturing (CDMO) capabilities. 

With a strong presence in key global markets, Sai Life Sciences has become one of the fastest-growing Indian CRDMOs, driven by a 117% growth in its commercial and late-stage product portfolio since 2019. The company operates research laboratories in major innovation hubs like Boston (US) and Manchester (UK), complemented by large-scale facilities in India, enabling cost-effective solutions for drug discovery and manufacturing. 

As of September 30, 2024, Sai Life Sciences had served over 280 pharmaceutical companies, including 18 of the top 25 global pharma companies. Its portfolio includes over 170 innovator pharmaceutical products, with several drugs approved and commercially available.

Sai Life Sciences is committed to sustainability, incorporating energy-saving measures, increasing the use of renewable energy, and reducing carbon emissions. The company is also a member of the Pharmaceutical Supply Chain Initiative (PSCI) and has received a silver rating for sustainability by EcoVadis. 

Peer Details

According to RHP, the following are the listed peers of Sai Life Sciences Limited:

  1. Divi's Laboratories Limited
  2. Suven Pharmaceuticals Limited
  3. Syngene International Limited

How To Check the Allotment Status of the Sai Life Sciences IPO?

Steps to check IPO allotment status on Angel One’s app:

  1. Log in to the Angel One app.
  2. Go to the IPO Section and then to IPO Orders.
  3. Select the individual IPO that you had applied for and check the allotment status.
  4. Angel One will notify you of your IPO allotment status via push notification and email.

How to apply for Sai Life Sciences IPO online?

  1. Login to Your Angel One Account: Open the Angel One app or website and log in with your credentials.
  2. Locate the IPO Section: Navigate to the 'IPO' section on the platform.
  3. Select IPO: Find and select the Sai Life Sciences IPO from the list of open IPOs.
  4. Enter the Lot Size: Specify the number of lots you want to bid for.
  5. Submit Your UPI ID: Enter your UPI ID to link your payment method and submit your application.
  6. Approve Funds: Once you receive the bid request on your UPI app, approve it by entering your UPI PIN.

Contact Details of Sai Life Sciences IPO 

Registered office: Plot No. DS-7,IKP Knowledge Park, Turkapally Village, ShameerpetMandal, Medchal–Malkajgiri District, Hyderabad 500078, Telangana, India

Phone: +9140 6815 6000

E-mail: investors@sailife.com 

Sai Life Sciences IPO Reservation

Investor Category

Shares Offered

QIB Shares Offered

Not more than 50.00% of the Net offer

Retail Shares Offered

Not less than 35.00% of the Net Issue

NII (HNI) Shares Offered

Not less than 15.00% of the Net Issue

Sai Life Sciences IPO Lot Size

Application

Lots

Shares

Amount

Retail (Min)

1

27

₹14,823

Retail (Max)

13

351

₹1,92,699

HNI (Min)

14

378

₹2,07,522

S-HNI (Max)

67

1,809

₹9,93,141

B-HNI (Min)

68

1,836

₹10,07,964

Sai Life Sciences IPO Promoter Holding

The company's promoters include Kanumuri Ranga Raju, Krishnam Raju Kanumuri, Kanumuri Mytrey, Sai Quest Syn Private Limited, Sunflower Partners, Lily Partners, Marigold Partners, and Tulip Partners.

Share Holding Pre-Issue

40.48%

Share Holding Post Issue

_

Key Performance Indicators for Sai Life Sciences IPO

The Sai Life Sciences IPO has a market capitalisation of ₹11,418.63 crore as of March 31, 2024.

KPI

Value

ROE

11.79%

ROCE

15.96%

RoNW

8.13%

P/BV

10.18

PAT Margin (%)

5.65

Sai Life Sciences IPO Prospectus

Sai Life Sciences IPO Registrar and Lead Managers

Sai Life Sciences IPO Lead Managers

  • Kotak Mahindra Capital Company Limited
  • Jefferies India Private Limited
  •  Morgan Stanley India Company Pvt Ltd
  •  Iifl Securities Ltd

Registrar for Sai Life Sciences IPO

 Kfin Technologies Limited

  • Contact Number: 04067162222, 04079611000
  • Email Address: sailifesciences.ipo@kfintech.com

Website: Sai Life Sciences IPO Registrar

Financial Performance of Sai Life Sciences Limited

Particulars Total Year ending on March 31, 2024Income Year ending on March 31, 2023 Year ending on March 31, 2022
Revenue from Operation (in ₹ million) 14,651.78 12,171.39 8,695.93
Profit After Tax (PAT) (in ₹ million) 828.09 99.89 62.26
Total Borrowings (in ₹ million) 7,101.63 6,992.29 7,513.18
Net Worth (in ₹ million) 9,743.37 8,872.86 8,777.58
Return on Capital Employed (%) 10.26 5.13 3.21
Return on Equity (%) 8.49 1.12 0.71
Debt/ Equity (x) 0.75 0.80 0.84
Earning Per Share (EPS)-in absolute ₹ 4.53 0.55 0.34

Know before investing

Strengths

6

  1. Sai Life Sciences is one of India's largest CRDMOs by revenue.

  2. Diverse product portfolio with 38 products and 7 blockbuster drugs.

  3. Fast-growing discovery capabilities with 34.77% CAGR from FY 2022-2024.

  4. Established relationships with over 230 new customers in recent years.

  5. Strong R&D infrastructure, offering integrated services and global talent.

  6. Fastest-growing CRDMO with improving profitability and revenue growth metrics.

Risks

6

  1. Dependent on biotechnology and pharmaceutical customers, facing industry-specific risks.

  2. Failure in R&D may lead to customer discontinuation and project loss.

  3. Compliance with stringent quality standards is critical to maintain reputation.

  4. Inability to secure regulatory licenses could harm operations and cash flow.

  5. Manufacturing delays or interruptions could lead to higher costs and risks.

  6. Heavy reliance on international revenue, facing risks of operational delays.

  • How to Apply in IPO
  • How to Check IPO Allotment Status
Play Button

Login to Angel One App / Website & click on IPO

Select desired IPO & tap on "Apply"

Enter UPI ID, set quantity/price & submit

Accept mandate on the UPI app to complete the process

Play Button

Login to Angel One App / Website

Choose IPO section on Home Page

Click IPO Orders

Chose the IPO application you want to view the status for

Sai Life Sciences Limited IPO FAQs

What is the Sai Life Sciences IPO?

Sai Life Sciences IPO is a book-built issue IPO. It will be open from December 11, 2024, to December 13, 2024.

When will Sai Life Sciences IPO be allotted?

The Basis of Allotment will happen on Monday, December 16, 2024.

When will Sai Life Sciences IPO open for subscription?

The IPO subscription window will open on December 11, 2024.

What minimum lot size can retail investors subscribe to?

The minimum lot size retail investors can subscribe to is 1 lot, and the lot size is 27 shares.

When will Sai Life Sciences Limited list on exchanges?

The listing date for Sai Life Sciences Limited is Wednesday, December 18, 2024.

What is the issue size of Sai Life Sciences IPO?

The issue size of the Sai Life Sciences IPO is up to ₹3,042.62 crore, with a fresh issue of ₹950.00 crore and an offer for sale of ₹2,092.62 crore.

What are the open and close dates of the Sai Life Sciences IPO?

The open and close dates for Sai Life Sciences IPO are from December 11, 2024 to December 13, 2024.

What would be the listing gains on the Sai Life Sciences IPO?

Listing gains cannot be ascertained before the listing of the IPO on the stock exchange.
How to increase your chances of getting a Sai Life Sciences IPO allotment?
1. Multiple Submissions: Use different Demat accounts to make multiple applications.
2. Higher Price Band Bidding: Opt for bidding at the cut-off price or higher price band.
3. Timely Subscription: Ensure you subscribe to the IPO within the specified time frame.

How do I approve the UPI mandate request for Sai Life Sciences IPO?

You must complete the payment process by logging in to your UPI handle and approving the payment mandate.

Can I submit more than one application for the public issue of Sai Life Sciences Limited using one PAN?

You can submit only one application using your PAN card.

How to read Sai Life Sciences Limited's financial statements?

To read Sai Life Sciences’s financial statements, download the IPO’s RHP document.

What is 'pre-apply' for Sai Life Sciences Limited IPO?

Pre-apply allows investors to apply for the Sai Life Sciences IPO two days before the subscription period opens, ensuring an early submission of your application.

If I pre-apply for the Sai Life Sciences Limited IPO, when will my order get placed?

Your order will be placed when the IPO opens for bidding, and a UPI request will follow within 24 hours.

When will I know if my Sai Life Sciences Limited IPO order is placed?

You will receive a notification once your order is successfully placed with the exchange after the bidding starts.

Who is the registrar of Sai Life Sciences IPO?

Kfin Technologies Limited is the registrar responsible for managing the IPO allotment process and handling investor queries.

Where is the Sai Life Sciences IPO getting listed?

Sai Life Sciences Limited IPO is a mainboard IPO that will be listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).